Abstract:Radiation therapy kills cancer cells through the generation of DNA double-strand breaks (DSB) which give rise to lethal chromosome aberrations. Intrinsic radiation resistance is mediated through several mechanisms including suppression of initial DSB formation by hypoxia in the tumor microenvironment and rapid repair of DSB by non-homologous end-joining (NHEJ). DNA-dependent protein kinase (DNA-PK) is a key element of NHEJ and is a well-validated target for tumor radiosensitization. However, DNA-PK inhibition has been demonstrated to radiosensitize normal tissues within the radiation field. Exploiting hypoxia to release DNA-PK inhibitors from hypoxia-activated prodrugs (HAPs) selectively in tumors is one strategy for enhancing tumor selectivity, with the advantage of sensitizing the most radioresistant (hypoxic) subpopulation and potentially sensitizing oxic tumor cells through a bystander effect. We recently discovered a new class of DNA-PK inhibitor based on an imidazo[4,5-c] pyridine-2-one scaffold. Our initial lead, SN39536, provided highly selective DNA-PK inhibition in biochemical and cell-based assays, potently radiosensitized parental HAP1 cells but not an isogenic knockout of PRKDC (encoding the DNA-PK catalytic subunit), and radiosensitized HCT116 cells both in vitro and as tumor xenografts. We explored three prodrug linker approaches (carbamate, ether, and quaternary ammonium salt linkers between nitroimidazole trigger units and DNA-PK inhibitors) to prepare HAPs of various DNA-PK inhibitors. The 2-nitroimidazole carbamate HAP, SN39884, was metabolized selectively in hypoxic cells to generate SN39536 in vitro, efficiently penetrated through hypoxic tumor tissue in multicellular layer cultures, and significantly radiosensitized HCT116 tumors in NIH-III mice at well-tolerated doses. However, the limited metabolic stability of SN39884 in mice led us to explore HAPs with an ether linker. Ether prodrug SN40458 released a phenolic DNA-PK inhibitor, SN39872, on reduction under hypoxic conditions. SN39872 provided robust sensitization of HCT116 cells under both oxic and hypoxic conditions in vitro, while the HAP, SN40458, only sensitized hypoxic cells. SN40458 provided significant radiosensitization of both HCT116 and UT-SCC-74B tumors in NIH-III mice, measured using an ex vivo clonogenic survival assay. Further optimization of prodrug metabolic stability is required before comparison of tumor and normal tissue radiosensitization by these second-generation HAPs and their corresponding DNA-PK inhibitors in mice. This comparison will provide a critical test of our hypothesis that hypoxia-dependent generation of the DNA-PK inhibitor enhances tumor selectivity. Citation Format: Lydia P. Liew, Cho R. Hong, Benjamin D. Dickson, Way W. Wong, Stephen M. Jamieson, William R Wilson, Michael P. Hay. Targeting tumor hypoxia with prodrugs of DNA-dependent protein kinase inhibitors [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: DNA Damage Repair: From Basic Science to Future Clinical Application; 2024 Jan 9-11; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2024;84(1 Suppl) nr A004.

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy

Recent advances in hypoxia-activated compounds for cancer diagnosis and treatment

Exploring chronic and transient tumor hypoxia for predicting the efficacy of hypoxia-activated pro-drugs

A dual-response drug delivery system with X-ray and ROS to boost the anti-tumor efficiency of TPZ <i>via</i> enhancement of tumor hypoxia levels

Hypoxia-Activated Theragnostic Prodrugs (HATPs): Current State and Future Perspectives

Abstract A004: Targeting tumor hypoxia with prodrugs of DNA-dependent protein kinase inhibitors

Recent Advances in the Study of Bioreductive Drugs Targeted Tumor Hypoxia

Recent Development of Transition Metal Complexes as Chemotherapeutic Hypoxia Activated Prodrug (HAP)

How to overcome (and exploit) tumor hypoxia for targeted gene therapy

TH-4000, a hypoxia-activated pan-HER inhibitor, shows excellent preclinical efficacy for the treatment of HER2+ breast cancer

A Research On The Mechanism Of Th-302 On Hypoxic Condition And Th-302 Combined With Radiation Applied In Gastrointestinal Tumors

A self-activating nanovesicle with oxygen-depleting capability for efficient hypoxia-responsive chemo-thermo cancer therapy

Targeting Hypoxia-Inducible Factor-1, for Cancer Treatment: Recent Advances in Developing Small-Molecule Inhibitors from Natural Compounds.

Hypoxia-regulated gene network in drug resistance and cancer progression

Hypoxia and pH co-triggered oxidative stress amplifier for tumor therapy

Hypoxic Tumor Therapy by Hemoglobin-Mediated Drug Delivery and Reversal of Hypoxia-Induced Chemoresistance

Therapeutic Targeting of Hypoxia-Inducible Factors in Cancer

TH‐302: A Highly Selective Hypoxia‐Activated Prodrug for Treating PARP Inhibitor–Resistant Cancers

Anti-hypoxia nanosized drug delivery systems improving cancer therapy

Hypoxia-responsive fluorescent nanoprobe for imaging and cancer therapy